A Case of Advanced Hepatocellular Carcinoma with Portal Vein Tumor Invasion that Showed Favorable Prognosis after Combined External Radiation Therapy and Sorafenib Therapy
Journal of Liver Cancer
;
: 134-138, 2016.
Article
in Korean
| WPRIM
| ID: wpr-76008
ABSTRACT
A prognosis of hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is dismal that the median survival is 2 to 4 months without treatment. Sorafenib, the standard regimen of advanced HCC, can prolong median survival only 1.5 months. A 50-year-old man with a history of chronic hepatitis B was diagnosed advanced HCC with PVTT. By a multidisciplinary medical team approach, the combination of 3-demensional conformal radiation therapy with sequential sorafenib was challenged. 4 months after initiation of treatment, he achieved partial response as modified response evaluation criteria in solid tumors criteria. Sorafenib was continued so far, and stable disease has been maintained up to now, without significant adverse effect.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Portal Vein
/
Prognosis
/
Thrombosis
/
Carcinoma, Hepatocellular
/
Hepatitis B, Chronic
/
Response Evaluation Criteria in Solid Tumors
Type of study:
Prognostic study
Limits:
Humans
Language:
Korean
Journal:
Journal of Liver Cancer
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS